


The Regulatory Environment for Human and Animal Therapies and the Advantages of Complementary Medicine Alternatives



Safe Harbour Statement

Except for historical data, the financial information circulated during this presentation contains statements that, by their very nature, are forward-looking and, therefore, involve time periods, risks and other factors, known or unknown, which are beyond the Company's control. Each of these factors may produce results or performances that differ significantly from expectations. No liability, present or future, derived from this can be assumed by Bioniche in any investment decision made following this presentation.

Corporate Structure

Bioniche Life Sciences Inc. (TSX: BNC)



A well-established life sciences firm with material revenues, multiple products, physical infrastructure and human resource capabilities.

Track record of developing proprietary technologies through to proof of commercial value in the human and veterinary fields.

Existing marketing and distribution infrastructure in key animal health markets, including the U.S., Canada, Australia and Europe.

Multi-product manufacturing capabilities – from biologics to pharmaceuticals, to cGMP standards.

A public company listed on the Toronto Stock Exchange with good trading liquidity.

Animal Health

Focus: Large Animals

➤ Immunotherapies

- ❖ Mycobacterial cell wall-based technologies
- ❖ Alternatives to use of human antibiotics in agriculture
- ❖ First to develop such products in veterinary medicine
- ❖ The source of Bioniche's human cancer technologies
- ❖ Potential partnered applications for companion animal cancers

➤ Reproductive technologies

- ❖ Global leader in assisted reproduction technologies
- ❖ Folltropin®-V is a cornerstone product respected internationally

➤ Hyaluronan-based technologies

- ❖ Improving equine performance

➤ Vaccines

- ❖ Novel technologies for unaddressed large animal diseases

Animal Health

Focus: Companion Animals

➤ Immunotherapies

- ❖ Mycobacterial cell wall-based technology
- ❖ Canine oncology

➤ Wound healing

- ❖ Natural, plant-based technology

➤ Anxiolytic

- ❖ Plant-based traditional medicine

Food Safety

Focus: Animal to Human Diseases

➤ ***E. coli* vaccine**

- ❖ Pathogen does not make cattle sick, but causes human illness
- ❖ Repeated outbreaks from meat, produce and water
- ❖ Extensively tested vaccine near approval in United States
- ❖ Development work ongoing on second generation vaccine
- ❖ Large potential domestic and international market


➤ **Other Food Safety Vaccines**

- ❖ Supporting discovery research on further vaccine candidates
- ❖ Potential targets include *Salmonella*, *Campylobacter* and *Listeria*

➤ **Manufacturing Capabilities**

- ❖ \$25 million government-funded facilities expansion underway
- ❖ Will produce >40 million doses of *E. coli* vaccine, plus other vaccines
- ❖ New facilities are scheduled for completion in 2011

E. Coli - From Cattle to Humans



E. coli is not just a "meat" problem

The Bioniche *E. coli* Vaccine



Studies of the vaccine have involved more than 30,000 cattle and have shown the following:

- Up to 99.5% reduction in shedding
- A 97.5% reduction in colonization
- 85% fewer animals shedding
- 63.9% reduced duration of shed in affected animals

A Canadian (CFIA) full license was granted Oct., 2008

USDA notification of eligibility for conditional license Feb., 2008

E. coli O157 Vaccine

➤ Natural source

- ❖ Bacterial extract from *Escherichia coli*

➤ Regulatory path

- ❖ “Biologic” in North America
- ❖ Regulated by U.S. Department of Agriculture;
Canadian Food Inspection Agency
- ❖ “Biologic” in Australia
- ❖ Import through AQIS
- ❖ “Biologic” in Europe



Human Health

Focus: Specialty Oncology Markets

➤ **Bladder Cancer** (Urocidin™ formulation of MCC)

- ❖ Novel intravesical immunotherapy based on MCC technology
- ❖ Completing its first Phase III trial in refractory patients
- ❖ Commencing a second Phase III trial
- ❖ Partnered with Endo Pharmaceuticals
- ❖ Large and un-crowded market opportunity


➤ **MCC-based Immunotherapies**

- ❖ Novel, patented and multi-functional immunotherapy
- ❖ Opportunity to develop for other types of cancer


➤ **Oligonucleotide Platform**

- ❖ Families of novel, patented oligonucleotides
- ❖ Potential next generation cancer immunotherapies

Mycobacterial Cell Wall-DNA Complex (MCC)



- MCC is prepared from *Mycobacterium phlei*, a non-pathogenic mycobacterium
- MCC is a well characterized *M. phlei* cell wall composition that contains bioactive DNA oligonucleotides
 - The DNA is associated with immune stimulant and anticancer activity
 - The cell wall functions as a biological drug delivery and immune stimulation system (recognition by cell receptors)
- MCC is sterile
- Urocidin™ is an MCC formulation for the treatment of bladder cancer



Immunotherapy

➤ Natural source

- ❖ A mycobacterium (*M. phlei*) found on grass, in soil

➤ Regulatory path

❖ Animal Health

- ❖ “Biologic” in North America
- ❖ Regulated by U.S. Department of Agriculture; Canadian Food Inspection Agency



❖ Human Health

- ❖ “Biologic” in North America
- ❖ Requires evidence of clinical efficacy through phased trials
- ❖ Regulated by U.S. Food & Drug Administration; Health Canada



Hyaluronan-Based Technologies

➤ Natural source

- ❖ Found in rooster comb; joints; eyes; connective tissue
- ❖ Bacterial fermentation (Bioniche products)

➤ Regulatory path

❖ Animal Health

- ❖ “Drug” in North America
- ❖ Regulated by U.S. Food & Drug Administration; Health Canada

❖ Human Health

- ❖ “Medical Device” in North America
- ❖ Requires evidence of clinical efficacy through phased trials
- ❖ Regulated by U.S. Food & Drug Administration; Health Canada



Natural Health Products

➤ Natural sources

- ❖ Plant extracts

➤ Regulatory path

❖ Animal Health

- ❖ Regulated as new drugs in Canada, but no specific rules attached; no rules in U.S.

❖ Human Health

- ❖ Regulated by new Natural Health Products Directorate in Canada; requires mandatory licensing



Bioniche Life Sciences Inc.



BEST
SMALL &
MEDIUM
EMPLOYERS IN CANADA



www.Bioniche.com

